AEON
AEON Biopharma·AMEX
--
--(--)
--
--(--)
AEON fundamentals
During Q3 2025, AEON Biopharma (AEON) reported revenue of --, a YoY change of 0.00%. Net income was -4.54M, a YoY change of 26.46%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | TTM |
|---|
Start Date | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 22, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | -- |
End Date | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 75.94M -- | -23.19M -- | -- -- | 161.23M -- | 0 -100.00% | 3.35M +114.42% | 3.49M -- | -- -- | 37.00K -- | -- -- |
Operating Expenses | 200.86K -- | 398.44K -- | 450.89K -- | 885.74K -- | 389.07K +93.70% | 427.20K +7.22% | 9.91M +2098.53% | 15.03M +1597.22% | 13.05M +3253.10% | 13.97M +3170.33% | 359.65M +3528.09% | 11.54M -23.24% | 74.15M +468.37% | 7.76M -44.46% | 4.02M -98.88% | 5.67M -50.90% | 3.95M -94.67% | 4.34M -44.10% | 2.53M -37.00% | 16.48M -- |
Selling, General and Administrative Expenses | -- -- | -- -- | -- -- | 1.94M -- | -- -- | -- -- | 2.44M -- | 5.50M +184.31% | 3.84M -- | 4.95M -- | 5.26M +116.13% | 4.68M -14.90% | 4.65M +21.04% | 3.32M -32.85% | 3.04M -42.18% | 2.63M -43.87% | 3.13M -32.78% | 3.26M -1.90% | 1.93M -36.50% | 10.95M -- |
Research and Development Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 7.48M -- | 9.53M -- | 9.21M -- | 9.03M -- | 354.39M +4639.71% | -341.14M -3680.07% | 5.73M -37.73% | 4.44M -50.81% | 972.00K -99.73% | 3.04M +100.89% | 825.00K -85.61% | 1.06M -76.03% | 597.00K -38.58% | 5.52M -- |
Other Operating Expenses | 200.86K -- | 398.44K -- | 450.89K -- | -1.05M -- | 389.07K +93.70% | 427.20K +7.22% | -- -- | -- -- | -- -- | -- -- | -- -- | 348.00M -- | 63.77M -- | -- -- | -- -- | 0 -100.00% | -- -- | 16.00K -- | -- -- | -- -- |
Operating Income | -200.86K -- | -398.44K -- | -450.89K -- | -885.74K -- | -389.07K -93.70% | -427.20K -7.22% | -9.91M -2098.53% | -15.03M -1597.22% | -13.05M -3253.10% | -13.97M -3170.33% | -283.71M -2762.04% | -34.73M -131.01% | -74.15M -468.37% | 153.47M +1198.51% | -4.02M +98.58% | -2.32M +93.32% | -462.00K +99.38% | -4.34M -102.83% | -2.49M +37.92% | -9.61M -- |
Non-Operating Income (Loss) | 6.52M -- | -3.63M -- | 6.11M -- | 1.13M -- | 3.16M -51.50% | 2.31M +163.73% | -525.00K -108.59% | -19.53M -1822.80% | -4.59M -245.23% | -1.41M -160.92% | -14.00M -2566.10% | 8.48M +143.45% | -43.87M -855.11% | 10.64M +855.61% | -2.15M +84.60% | 4.40M -48.11% | 9.56M +121.79% | -2.30M -121.66% | -2.04M +5.10% | 9.61M -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | 79.69K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -15.78M -- | 15.78M -- | -- -- | -- -- | 81.00K +100.51% | 19.93M +26.34% | -- -- | -- -- | 0 -100.00% | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | 10.71M -- | -- -- | -- -- | -- -- | -4.42M -141.22% | -- -- | -- -- | 1.59M -- | 725.00K +116.42% | -20.99M -- | 7.70M -- | -2.25M -241.56% | 4.14M +470.76% | 85.10M +505.42% | -2.40M -131.12% | -2.11M +6.30% | 84.73M -- |
Other Non-Operating Income (Loss) | 6.51M -- | -3.66M -- | 6.09M -- | -9.60M -- | 3.03M -53.42% | 2.17M +159.47% | -525.00K -108.62% | -15.11M -57.44% | -4.59M -251.44% | -1.41M -164.77% | 186.00K +135.43% | -8.02M +46.96% | -22.88M -398.11% | 2.94M +308.74% | 19.00K -89.78% | -19.67M -145.33% | -75.54M -230.19% | 92.00K -96.87% | 68.00K +257.89% | -95.05M -- |
Net Interest Expense | -8.32K -- | -28.72K -- | -21.43K -- | 58.47K -- | -129.59K -1457.71% | -137.38K -378.41% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 8.32K -- | 28.72K -- | 21.43K -- | -58.47K -- | 129.59K +1457.71% | 137.38K +378.41% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | 6.32M -- | -4.03M -- | 5.66M -- | 247.87K -- | 2.77M -56.11% | 1.88M +146.81% | -10.44M -284.45% | -34.56M -14043.78% | -17.64M -736.01% | -15.38M -916.27% | -297.71M -2752.18% | -26.24M +24.07% | -118.02M -569.07% | 164.11M +1167.12% | -6.17M +97.93% | 2.08M +107.93% | 9.10M +107.71% | -6.64M -104.05% | -4.54M +26.46% | -3.00K -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | 16.96K -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -389.81K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Income Tax Adjustments | -- -- | -- -- | -- -- | 389.81K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | 6.32M -- | -4.03M -- | 5.66M -- | 247.87K -- | 2.77M -56.11% | 1.87M +146.39% | -10.44M -284.45% | -34.56M -14043.78% | -17.64M -736.01% | -15.38M -923.68% | -297.71M -2752.18% | -26.24M +24.07% | -118.02M -569.07% | 164.11M +1167.12% | -6.17M +97.93% | 2.08M +107.93% | 9.10M +107.71% | -6.64M -104.05% | -4.54M +26.46% | -3.00K -- |
Net Income Attributable to Owners of the Company | 6.32M -- | -4.03M -- | 5.66M -- | 247.87K -- | 2.77M -56.11% | 1.87M +146.39% | -10.44M -284.45% | -34.56M -14043.78% | -17.64M -736.01% | -15.38M -923.68% | -297.71M -2752.18% | -26.24M +24.07% | -118.02M -569.07% | 164.11M +1167.12% | -6.17M +97.93% | 2.08M +107.93% | 9.10M +107.71% | -6.64M -104.05% | -4.54M +26.46% | -3.00K -- |
Net Income Attributable to Common Stockholders | 6.32M -- | -4.03M -- | 5.66M -- | 247.87K -- | 2.77M -56.11% | 1.87M +146.39% | -10.44M -284.45% | -34.56M -14043.78% | -17.64M -736.01% | -15.38M -923.68% | -297.71M -2752.18% | -26.24M +24.07% | -118.02M -569.07% | 164.11M +1167.12% | -6.17M +97.93% | 2.08M +107.93% | 9.10M +107.71% | -6.64M -104.05% | -4.54M +26.46% | -3.00K -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -10.44M -- | -34.56M -- | -17.64M -- | -15.38M -- | -297.71M -2752.18% | -26.24M +24.07% | -118.02M -569.07% | 164.11M +1167.12% | -- -- | 2.08M +107.93% | 9.10M +107.71% | -6.64M -104.05% | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -10.44M -- | -34.56M -- | -17.64M -- | -15.38M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Basic EPS | 0.29 -- | -0.12 -- | 0.16 -- | 0.01 -- | 0.08 -72.41% | 0.05 +141.67% | -0.08 -150.00% | -1 -10100.00% | -0.13 -262.50% | -0.11 -320.00% | -8.01 -9912.50% | -0.71 +29.00% | -227.87 -175184.62% | 304 +276463.64% | -11.24 -40.32% | 0.05 +107.04% | 2.28 +101.00% | -0.6 -100.20% | -0.39 +96.53% | 1.34 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -8.01 -- | -- -- | -227.87 -- | 304 -- | -11.24 -40.32% | -- -- | 2.28 +101.00% | -0.6 -100.20% | -0.39 +96.53% | -- -- |
Diluted EPS | 0.29 -- | -0.12 -- | 0.16 -- | -- -- | 0.08 -72.41% | 0.05 +141.67% | -0.08 -150.00% | -- -- | -0.13 -262.50% | -0.11 -320.00% | -8.01 -9912.50% | -- -- | -227.87 -175184.62% | 304 +276463.64% | -11.24 -40.32% | -- -- | 2.28 +101.00% | -0.6 -100.20% | -0.39 +96.53% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -8.01 -- | -- -- | -227.87 -- | 304 -- | -11.24 -40.32% | -- -- | 2.28 +101.00% | -0.6 -100.20% | -0.39 +96.53% | -- -- |
You can ask Aime
What were the key takeaways from AEON Biopharma’s earnings call?What is AEON Biopharma's latest dividend and current dividend yield?What does AEON Biopharma do and what are its main business segments?What is the revenue and EPS growth rate for AEON Biopharma year over year?What guidance did AEON Biopharma's management provide for the next earnings period?Did AEON Biopharma beat or miss consensus estimates last quarter?What were the key takeaways from AEON Biopharma's earnings call?What factors drove the changes in AEON Biopharma's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
